The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S4-S5 , October 2007

Cubicin Outcomes Registry and Experience (CORE) Methodology

  • Kenneth V.I. Rolston, MD

      Affiliations

    • M. D. Anderson Cancer Center, University of Texas, Houston, Texas, USA
    • ,
  • John Segreti, MD

      Affiliations

    • Rush University Medical Center, Chicago, Illinois, USA
    • ,
  • Kenneth C. Lamp, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA.
    • Corresponding Author InformationRequests for reprints should be addressed to Kenneth C. Lamp, PharmD, Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421.
    • ,
  • Lawrence V. Friedrich, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA.

References 

  1. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  2. Fowler VG, Boucher HW, Corey R, et al. S. aureus Endocarditis and Bacteremia Study Group Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–656

 Please see the Author Disclosure section at the end of this article.

PII: S0002-9343(07)00658-4

doi: 10.1016/j.amjmed.2007.07.008

The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S4-S5 , October 2007

Article Tools